Detalles de la búsqueda
1.
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy.
Future Oncol
; 18(23): 2593-2604, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35722877
2.
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Breast Cancer Res
; 22(1): 33, 2020 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32252811
3.
Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs.
Tumori
; : 3008916241246659, 2024 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38623748
4.
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
Clin Lung Cancer
; 24(7): 631-640.e2, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37775370
5.
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Lung Cancer
; 186: 107417, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37918061
6.
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.
J Thorac Oncol
; 18(8): 1070-1081, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37094664
7.
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
J Immunother Cancer
; 11(6)2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37286305
8.
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
J Natl Cancer Inst
; 115(7): 796-804, 2023 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37042716
9.
Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.
Front Oncol
; 12: 902967, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35756673
10.
Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.
Eur J Cancer
; 174: 31-36, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35970033
11.
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis.
Eur J Cancer
; 166: 202-207, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35306318
12.
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy.
Cancers (Basel)
; 14(2)2022 Jan 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35053597
13.
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
Clin Lung Cancer
; 23(1): e17-e28, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34334296
14.
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Clin Lung Cancer
; 23(7): e489-e499, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35948460
15.
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients.
Front Oncol
; 12: 1078822, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36755856
16.
Comparison of outcomes of central venous catheters in patients with solid and hematologic neoplasms: an Italian real-world analysis.
Tumori
; 107(1): 17-25, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32529962
17.
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors.
J Pers Med
; 11(5)2021 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34069851
18.
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Eur J Cancer
; 149: 235-248, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33820681
19.
Is hyperprogressive disease a specific phenomenom of immunotherapy?
Explor Target Antitumor Ther
; 1(6): 427-433, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-36046388
20.
Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers.
Clin Sarcoma Res
; 10: 17, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32874547